Supplementary Data for: Efficacy and safety of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open label extension period of the Phase 2 STRIDE study
Published: 19 September 2025| Version 1 | DOI: 10.17632/vwzkp28fwb.1
Contributors:
Kim Papp, Shahram Jacobs, Howard Sofen, Michael Bukhalo, Elisa Muscianisi, Grace Ma, Gabriel Lau, Michelle Bettinger, Roman Rubio, Elena Hitraya, Andrew BlauveltDescription
This dataset contains supplementary data for the following publication: Efficacy and safety of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open label extension period of the Phase 2 STRIDE study published in the Journal of the American Academy of Dermatology. Supplementary material includes study design details, patient eligibility criteria, list of investigators, 2 supplementary tables, and 5 supplementary figures.
Files
Categories
Tyrosine Kinase Inhibitor, Psoriasis, Clinical Trial Results
Funders
- Alumis Inc.